Tag Archives: Lung

FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Print this page South San Francisco, CA — December 3, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane ® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults… Read More »

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Pfizer’s aging Xalkori is the drug to beat in ALK-positive non-small cell lung cancer arena. And that’s just the arena Takeda is aiming for with earlier use of its own treatment Alunbrig. After 25 months of treatment, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC, as assessed by… Read More »

Chemo-Loaded Nanoparticles Piggyback on Red Blood Cells to Treat Lung Cancer

Scientists at Harvard’s Wyss Institute have developed a technique to deliver chemotherapy to the lungs using red blood cells. The method involves binding chemotherapy-loaded nanoparticles to red blood cells, which are then injected into the bloodstream. Once the red blood cells reach the lungs they have to squeeze through the small capillaries and the resulting… Read More »

FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)

Print this page September 06, 2019 — The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. “Patients suffering from… Read More »